Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sophiris Bio Inc T.SHS


Primary Symbol: SPHS

Sophiris Bio Inc is a clinical-stage biopharmaceutical company. It focuses on the development of products for the treatment of urological diseases. The company's product portfolio includes topsalysin (PRX302), for the treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. Topsalysin is a genetically modified recombinant protein which is selectively activated by enzymatically active prostate-specific antigen (PSA), which is only present in the prostate, leading to localized cell death and tissue disruption without damage to neighboring tissue and nerves. Geographically all the operations of the company are functioned in the United States.


EXPM:SPHS - Post by User

Comment by melaurianon May 19, 2018 11:09am
205 Views
Post# 28056376

RE:Useful Data and Articles

RE:Useful Data and ArticlesA six-month data read-out on 38 patients currently enrolled in a PH2b prostate cancer trial is due around the end of the 2nd quarter. Some of these patients may opt for a second dose of Topsalysin, these patients will have a final data read-out released at year end, which will complete this 12 month PH2b prostate cancer study. For more information please visit: https://sphs2017.wordpress.com
Bullboard Posts
Next >>